Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Expansion of “Mixed Care” Cited in Outline for New Growth Strategy
June 12, 2014
- MHLW to Seek Opinions on Abe’s New Mixed Care Plan from Advisory Panels
June 11, 2014
- PM Abe Vows to Forge New System to Accelerate Mixed Care
June 11, 2014
- Health Minister Still Cautious about Annual Drug Price Revision
June 11, 2014
- Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
- Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
- No Complaints Received So Far for Penalty Fee Cuts: MHLW Official
June 10, 2014
- Japan Sees 53-Month Designation Lag, 54-Month Approval Lag for Orphan Drugs
June 9, 2014
- MHLW Designates 20 Products including Allegra FX as Drugs Requiring Face-to-Face Consultations
June 9, 2014
- Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
- JRCS to Use Nucleic Acid Testing on Individual Samples of Donated Blood: PAFSC Committee
June 9, 2014
- MHLW Rejects Proposal to Abolish Market Expansion Re-Pricing Rule
June 6, 2014
- LDP Members with Vested Interests to Oppose Annual Drug Price Revision
June 6, 2014
- MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
- MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
- MHLW Orders Revision of Package Inserts to Urge Caution in Concurrent Use of ARBs and ACE Inhibitors
June 5, 2014
- MOF Budget Examiner Calls for Revising Price-Gap Rule for Key Premium
June 4, 2014
- MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
- Gov’t to Discuss Further Reforms of Mixed Care System, Commit to Deregulation: PM Abe
June 4, 2014
- “Difficult” to Include Annual NHI Price Revision in Govt Blueprint: Minister
June 4, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…